Navigation Links
United BioSource Scientist Leads Development of New Guidelines for Drug Reimbursement by German Government
Date:2/19/2008

New Methods Delivered to German Government in January

BETHESDA, Md., Feb. 19 /PRNewswire/ -- United BioSource Corporation's (UBC) director of global health economics has just delivered to the German government one of the most significant revisions of drug policy produced in Europe in more than a decade.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070910/NEM007LOGO )

The 70-page report, commissioned last year by Germany's Institute for Quality and Efficiency In Healthcare (IQWiG), will be used by the German government to evaluate drugs and devices and to set prices and reimbursement levels for those products. The document is expected to be widely influential both inside and outside of Germany, the third largest pharmaceutical market in the world.

The director and main author of the report, Jaime Caro, MD, Senior Vice President of UBC, was selected by the German government to head the eight- member international panel because of his recognized authority in the design and implementation of cutting-edge modeling and analytic techniques for health technology assessments, particularly in determining the value and safety of medical products.

According to Dr. Caro, "It was an immense honor to lead such a distinguished panel in developing pioneering methods for economic evaluation. These methods will have a strong influence on the efforts of society to control health care costs. I am very glad that with my team of experienced professionals at UBC, we can work towards improving health outcomes."

Made public in Berlin on January 24, 2008 by IQWiG, the findings and recommendations of the expert panel, if accepted, will directly impact the pricing and reimbursement of pharmaceuticals, biologicals and medical devices in Germany, which has the largest population of any EU nation.

Dr. Caro recommends that companies with marketed products and products in development set up a process to assess where the pharmaceuticals fall under the new methods and "be prepared to defend their position, understanding that they might need additional data or other strategies."

The report is titled Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System.

United BioSource Corporation (UBC) is a global pharmaceutical services organization that helps emerging and established life science companies develop and commercialize medical products. UBC specializes in offering new and innovative ways to study drugs and devices by offering expertise in science, strategy and execution.

UBC is headquartered in Bethesda, Maryland, with offices in the United States, Canada, Western Europe (including Cologne, Germany), Eastern Europe and South America. For more information, visit http://www.unitedbiosource.com or call 866-458-1096.

CONTACT: Tess Drahzal, +1 (240) 644-0420, info@unitedbiosource.com
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Jaime Caro, MD http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=73597


'/>"/>
SOURCE United BioSource Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
2. Davis Vision, United Concordia Free Clinic Promotes Childrens Eye and Dental Health
3. United Concordia Celebrates National Childrens Dental Health Month
4. UnitedHealthcare of the River Valley Acts to Help Tennessee Victims of Storm Devastation
5. Access Is Not Enough: What It Will Take to Transform Health Care in the United States
6. United Concordia Unveils New Online Capabilities for Producers
7. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
8. MedWaves, Inc. Announces Receipt of United States Food and Drug Administration 510k Clearance to Market Its Patented Microwave Coagulation/Ablation System
9. Peninsula United Methodist Homes Completes Enterprise-Wide Deployment of AccuNurse Voice-Assisted Care
10. USP Publishes Spanish Edition of United States Pharmacopeia and National Formulary
11. United States Joins False Claims Act Cases Against Three New Jersey Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology: